Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.

Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.